Equillium (EQ) Competitors $1.47 -0.02 (-1.34%) As of 09:42 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EQ vs. ALT, CGEM, RCKT, LBRX, TVRD, IMRX, CTNM, ENGN, AMRN, and TKNOShould you be buying Equillium stock or one of its competitors? The main competitors of Equillium include Altimmune (ALT), Cullinan Therapeutics (CGEM), Rocket Pharmaceuticals (RCKT), LB Pharmaceuticals (LBRX), Tvardi Therapeutics (TVRD), Immuneering (IMRX), Contineum Therapeutics (CTNM), enGene (ENGN), Amarin (AMRN), and Alpha Teknova (TKNO). These companies are all part of the "pharmaceutical products" industry. Equillium vs. Its Competitors Altimmune Cullinan Therapeutics Rocket Pharmaceuticals LB Pharmaceuticals Tvardi Therapeutics Immuneering Contineum Therapeutics enGene Amarin Alpha Teknova Altimmune (NASDAQ:ALT) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations. Do insiders and institutionals hold more shares of ALT or EQ? 78.1% of Altimmune shares are held by institutional investors. Comparatively, 27.1% of Equillium shares are held by institutional investors. 4.4% of Altimmune shares are held by insiders. Comparatively, 30.3% of Equillium shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is ALT or EQ more profitable? Equillium has a net margin of 0.00% compared to Altimmune's net margin of -438,730.03%. Altimmune's return on equity of -62.63% beat Equillium's return on equity.Company Net Margins Return on Equity Return on Assets Altimmune-438,730.03% -62.63% -55.29% Equillium N/A -139.56%-90.56% Which has higher valuation & earnings, ALT or EQ? Equillium has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Equillium, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAltimmune$20K17,365.16-$95.06M-$1.18-3.33Equillium$41.10M2.13-$8.07M-$0.56-2.63 Does the media favor ALT or EQ? In the previous week, Altimmune had 13 more articles in the media than Equillium. MarketBeat recorded 17 mentions for Altimmune and 4 mentions for Equillium. Equillium's average media sentiment score of 0.75 beat Altimmune's score of 0.01 indicating that Equillium is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Altimmune 1 Very Positive mention(s) 1 Positive mention(s) 13 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Equillium 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate ALT or EQ? Altimmune currently has a consensus price target of $17.40, suggesting a potential upside of 342.19%. Equillium has a consensus price target of $1.00, suggesting a potential downside of 31.97%. Given Altimmune's stronger consensus rating and higher probable upside, equities analysts plainly believe Altimmune is more favorable than Equillium.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Altimmune 2 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.38Equillium 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Which has more risk & volatility, ALT or EQ? Altimmune has a beta of 0.07, indicating that its stock price is 93% less volatile than the S&P 500. Comparatively, Equillium has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500. SummaryAltimmune and Equillium tied by winning 8 of the 16 factors compared between the two stocks. Get Equillium News Delivered to You Automatically Sign up to receive the latest news and ratings for EQ and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EQ vs. The Competition Export to ExcelMetricEquilliumMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$87.47M$3.35B$6.12B$10.65BDividend YieldN/A2.29%5.70%4.74%P/E Ratio-2.6321.4185.6226.85Price / Sales2.13466.25620.08135.13Price / CashN/A47.6737.7861.77Price / Book2.7210.0613.086.70Net Income-$8.07M-$52.22M$3.30B$276.44M7 Day Performance-0.68%4.25%3.94%2.48%1 Month Performance-21.81%12.50%8.39%8.79%1 Year Performance54.72%26.68%86.55%34.41% Equillium Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EQEquillium0.9898 of 5 stars$1.47-1.3%$1.00-32.0%+59.5%$87.47M$41.10M-2.6340News CoverageGap DownALTAltimmune3.227 of 5 stars$3.79-5.3%$17.40+359.1%-35.6%$353.03M$20K-3.2150CGEMCullinan Therapeutics1.9961 of 5 stars$5.97+0.2%$26.00+335.5%-63.3%$352.08MN/A-1.8530RCKTRocket Pharmaceuticals4.7683 of 5 stars$3.28+0.6%$16.73+410.2%-81.3%$351.77MN/A-1.31240LBRXLB PharmaceuticalsN/A$15.24-1.3%N/AN/A$346.52MN/A0.0016Trending NewsAnalyst ForecastAnalyst RevisionGap DownTVRDTvardi Therapeutics3.1183 of 5 stars$36.90+1.6%$64.25+74.1%N/A$340.59M$7.14M0.0080IMRXImmuneering3.9034 of 5 stars$6.75-16.5%$17.75+163.0%+149.4%$335.89MN/A-3.5760Short Interest ↑High Trading VolumeCTNMContineum Therapeutics2.4854 of 5 stars$11.82-0.8%$22.20+87.8%-34.1%$334.26M$50M-5.3731ENGNenGene3.213 of 5 stars$6.45-0.6%$19.50+202.3%+4.8%$332.23MN/A-3.3931AMRNAmarin0.4277 of 5 stars$16.08+0.5%$12.00-25.4%+67.2%$330.92M$228.61M-4.38360High Trading VolumeTKNOAlpha Teknova1.6261 of 5 stars$5.65-6.9%$10.00+77.0%+8.3%$324.84M$37.74M-13.45240 Related Companies and Tools Related Companies Altimmune Competitors Cullinan Therapeutics Competitors Rocket Pharmaceuticals Competitors LB Pharmaceuticals Competitors Tvardi Therapeutics Competitors Immuneering Competitors Contineum Therapeutics Competitors enGene Competitors Amarin Competitors Alpha Teknova Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EQ) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredTrump to get REVENGE on the banks??Rumors are swirling that Trump could target the banking system by upending the $5 trillion-a-day SWIFT network...The Oxford Club | SponsoredThis is the “End of Tesla” as we know it…Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Equillium, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Equillium With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
